Allinaire Therapeutics is a biopharmaceutical company specializing in the development of novel therapeutics for cardiopulmonary diseases. The company is currently advancing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies as a potential disease-modifying treatment for Pulmonary Arterial Hypertension (PAH). Operating in the healthcare and biotechnology market, Allinaire serves patients suffering from severe cardiopulmonary conditions. The business model revolves around the research, development, and eventual commercialization of these innovative therapies. Revenue is generated through the successful development and licensing of their proprietary treatments, as well as potential partnerships and collaborations with larger pharmaceutical companies. The company leverages licensed technology from Indiana University and is led by a team of experienced professionals with extensive backgrounds in pulmonary, critical care, and drug discovery.

Keywords: biopharmaceutical, cardiopulmonary, PAH, monoclonal antibodies, EMAP II, cytokine, inflammation, endothelial, apoptosis, novel therapeutics.